In addition to its antitumor efficacy by binding HER3 ligand and the release of the cytotoxic payload in the tumor cells (7), patritumab deruxtecan enhanced the infiltration of innate and adaptive immune cells in preclinical models (8). This evidence concerns the gene ERBB3 and neoplasm.